365,833 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Bought by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 365,833 shares of the company’s stock, valued at approximately $8,126,000. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.18% of Cellebrite DI as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in Cellebrite DI in the fourth quarter worth $9,995,000. Aigen Investment Management LP grew its position in Cellebrite DI by 16.9% in the fourth quarter. Aigen Investment Management LP now owns 52,595 shares of the company’s stock worth $1,159,000 after acquiring an additional 7,598 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Cellebrite DI in the fourth quarter worth $234,000. Steward Partners Investment Advisory LLC grew its position in Cellebrite DI by 12.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock worth $299,000 after acquiring an additional 1,463 shares in the last quarter. Finally, Tower View Wealth Management LLC boosted its position in Cellebrite DI by 1.3% during the fourth quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company’s stock valued at $2,915,000 after buying an additional 1,660 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CLBT has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Friday, February 14th. Lake Street Capital upped their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI presently has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Trading Up 0.5 %

Shares of NASDAQ:CLBT opened at $17.57 on Monday. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -12.64, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The company has a 50-day moving average price of $21.87 and a 200-day moving average price of $19.71. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.